Background. As malaria control is intensified, pregnant women may be less exposed to malaria, thus affecting the acquisition of protective antibody.
Plasmodium falciparum malaria remains entrenched in sub-Saharan Africa and the Pacific Islands. Women in their first pregnancy are particularly susceptible to malaria [1, 2] , in part because of the ability of P. falciparuminfected erythrocytes (IEs) to sequester within the placenta [3, 4] . Placental-binding IEs express different variant surface antigens (VSA) from IEs that cause malaria in childhood, so they are not recognized by antibodies conferring existing immunity to malaria [5, 6] .
Malaria in pregnancy (MiP) increases the risk of maternal anemia at delivery and low birth weight, which are important causes of maternal and infant mortality [7] [8] [9] . Antibodies to placental-binding IEs are associated with protection against MiP and are acquired in a gravidity-dependent manner [1, 6, 10] . Development of these antibodies is influenced by transmission intensity, human immunodeficiency virus (HIV) infection, and the use of malaria-prevention strategies, including insecticide-treated bed nets (ITNs) [11] [12] [13] [14] .
As malaria exposure declines, immunity may decrease. This is indirectly supported by data showing that, as infection prevalence fell in Malawian pregnant women, parasite densities increased among infected women [15] . Taken together, if exposure to MiP falls, antibody to placental-binding IEs may be less developed, susceptibility to MiP may spread into later gravidities, and among the infants who are infected, the consequences may be more severe [16] .
Malaria prevalence in pregnancy has declined substantially in Malawi and Papua New Guinea (PNG), and we hypothesized that this is associated with reduced levels of pregnancy-specific malaria immunity but not with immunity to non-pregnancyassociated antigens.
MATERIALS AND METHODS

Ethics Approval
Ethics approval was obtained from the College of Medicine Research Ethics Committee, University of Malawi (P99/00/91R, P00/01/107), the PNG Institute of Medical Research Institutional Review Board (08. 15 
Study Sites and Participants
Plasma samples came from 2 cohorts. In Malawi, pregnant women were recruited at delivery between 1999 and 2006 from the maternity unit of Queen Elizabeth Central Hospital in Blantyre, as previously described [15] . Women were classified on the basis of enrollment time into early (enrollment years, 1999-2000; parasite prevalence, 25.2%) and late (enrollment years, [2004] [2005] [2006] ; parasite prevalence, 6.2%) groups. In PNG, pregnant women were recruited at the first antenatal care (ANC) visit and followed to delivery at rural clinics in Madang Province between 2005 and 2012. Women were classified on the basis of enrollment time into early (enrollment years, [2005] [2006] [2007] ; parasite prevalence, 18.0%) and late (enrollment years, 2010-2012; parasite prevalence, 3.1%) groups. In the latter period, women were randomized to receive 3 courses of intermittent preventive treatment (IPTp) with sulfadoxinepyrimethamine (SP) and azithromycin (AZ) during pregnancy or to receive a single course of SP and chloroquine (CQ). ITN use was documented.
Samples were collected at delivery (and at the first ANC visit in PNG), and malaria parasite infection was defined as the detection of parasites by concurrent peripheral or placental blood microscopy. Because current infection increases antibody responses [17] , only samples from uninfected women were selected. We did not study primigravidae because, when uninfected, they have very low levels of antibodies against placental-binding IEs [17] . All available samples from women experiencing pregnancies 2-4 were used.
In the PNG cohort, paired enrollment and delivery samples were tested together, to determine whether declining exposure impairs the acquisition of antibody over the course of pregnancy. Samples were tested in duplicate and were randomized to minimize testing samples from the same year together.
Parasite and Cell Cultures
The laboratory-adapted P. falciparum lines CS2 ( placental binding) and E8B-ICAM (endothelial binding) were cultured as described elsewhere [18] . THP-1 monocyte-like cells [19] were cultured as previously described [20] .
Assays of Immunoglobulin G (IgG) to Schizont Extract, Merozoite Antigens, and VAR2CSA-DBL5 ɛ Antibody responses to recombinant P. falciparum antigens were measured by enzyme-linked immunosorbent assay (ELISA), using established methods [21] . Microtiter plates were coated with 50 µL of individual targets diluted in phosphate-buffered saline (PBS) at the following dilutions and concentrations: schizont extract [22] from CS2 IEs, 1:2000 dilution; MSP2 from FC27, 0.5 µg/mL [21] ; MSP3 from 3D7 full ectodomain, 2 µg/mL [23] ; PfRh2 (construct PfRh2-2030 from 3D7), 0.5 µg/mL [24] ; and VAR2CSA-DBL5 ɛ from 3D7, 0.5 µg/mL [25, 26] . Plasma was added in duplicate at a 1:1000 dilution. A standard curve generated from serial dilution of our positive control ( pooled from 44 pregnant women with high antibody responses) was used to convert ODs into antibody levels represented by arbitrary units, where the positive control is equivalent to 100 U.
Merozoite Phagocytosis Assay
Antibody opsonic phagocytosis of merozoites was performed using a recently developed assay (Osier, Feng, and Beeson, unpublished material). Whole merozoites were obtained as described elsewhere [27] . In brief, merozoites were stained with 10 µg/mL ethidium bromide (Sigma-Aldrich) for 30 minutes and washed thrice at 2200 × g for 5 minutes [27] . The cell density was determined using relative counting against CountBright Absolute Counting Beads (Invitrogen) as per the manufacturer's protocol. The merozoites were resuspended at 5 × 10 7 merozoites/mL in Roswell Park Memorial Institute 1640 medium (RPMI)-HEPES, and 30 µL of suspension was opsonized with 3.5 µL of plasma (1:250 dilution) in newborn calf serum (NCS; Gibco)-coated 96-well U-bottomed plates for 1 hour in the dark. The cells were washed thrice, resuspended in 150 µL of THP-1 medium (RPMI supplemented with 10% fetal bovine serum, 1% penicillin-streptomycin-glutamine, and 25 mM HEPES [Gibco]), and 50 µL of suspension was transferred in duplicate into fresh NCS-coated 96-well U-bottom plates, followed by addition of 100 µL of THP-1 cells at 5 × 10 5 cells/mL (ratio of target to effector, 10:1). The cells were incubated in 5% humidified CO 2 at 37°C for 10 minutes. Phagocytosis was stopped by centrifugation at 4°C at 350 × g for 5 minutes and washed thrice with FACS buffer. THP-1 cells were fixed in 2% paraformaldehyde (PFA) in PBS before acquisition with a FACSCantoII flow cytometer (BD Biosciences). The background level of nonspecific phagocytosis observed with the no-plasma (negative) control was set to be <5%, and the data are specified as the percentage of THP-1 cells that ingested free merozoites.
Measuring Levels of IgG to VSAs
Total IgG levels against VSAs expressed on CS2 and E8B-ICAM IEs was measured as described elsewhere [28] , with slight modifications. In brief, trophozoite-stage IEs at 4%-8% parasitemia were washed thrice with 1% NCS in PBS, resuspended at 0.2% hematocrit in PBS/NCS, and incubated for 30 minutes with test plasma (1:20 dilution, in duplicate) in NCS-coated 96-well U-bottomed plates at room temperature. IEs were washed, incubated with rabbit anti-human IgG (1:100 dilution, Dako), and washed 3 times. IEs were incubated in the dark with AlexaFluor 647 donkey anti-rabbit IgG (1:500 dilution, Invitrogen) containing 10 µg/mL ethidium bromide. IEs were washed and resuspended in 2% PFA. The data are specified as the relative geometric mean fluorescence intensity (MFI), calculated as the percentage of the MFI of a positive (hyperimmune pooled sera) control remaining after subtraction of the MFI of a negative control, which was the average MFI of samples from 6 Melbournian donors.
Opsonic Phagocytosis Assay
We improved our previously established phagocytosis assay [20] to measure opsonic antibody responses to CS2 and E8B-ICAM IEs. In summary, trophozoite-stage IEs were purified by density gradient centrifugation [20] , stained with 10 µg/mL ethidium bromide, washed thrice, and resuspended at 1.67 × 10 7 IEs/mL. Thirty microliters of the IE suspension were then opsonized with 3.3 µL (1:10 dilution) of plasma in NCS-coated 96-well U-bottomed plates for 1 hour in the dark. IEs were washed thrice, resuspended in 50 µL of THP-1 medium, and aliquoted in duplicate into NCS-coated 96-well U-bottomed plates, and THP-1 cells (25 µL at 5 × 10 5 cells/ mL; ratio of target to effector, 10:1) were added. The cells were incubated at 37°C in 5% humidified CO 2 for 40 minutes. Phagocytosis was stopped, and unphagocytosed IEs were lysed [20] . THP-1 cells were washed and fixed in 2% PFA [20] . Results were represented as the percentage of THP-1 cells that ingested IEs. A sample caused phagocytosis when ingestion was greater than the mean value + 3SDs for negative controls. Assays for total IgG and opsonic IgG to IEs were performed using a HyperCyt CyAn flow cytometer (Beckman Coulter), and in each assay discordant samples were reanalyzed using our published rules [28] .
Antibody Responses in the PNG Cohort
To assess whether antibody levels changed between enrollment and delivery, we used the antibody levels for each sample and used our published rules to resolve discordant results [28] . Samples with antibody levels exhibiting an adjusted mean variance of <20% and a mean difference of <10% between enrollment and delivery were categorized as having unchanged antibody responses, whereas samples with an adjusted mean variance of >20% and a mean difference of >10% were classified as having either decreased or increased antibody responses.
Statistical Analyses
Data obtained from assays were combined with clinical information about the study participants and were analyzed using Stata v11.2 (Stata). In some instances, analyses were done in GraphPad Prism v5 (GraphPad Software).
The Mann-Whitney U test was performed on continuous nonparametric variables, and categorical variables were assessed using χ 2 tests. Multiple linear regression models were performed to determine the association between continuous and categorical variables. Potential confounders, including gravidity, age, IPTp and ITN use, and maternal characteristics, were included.
RESULTS
Study Populations Characteristics
In Malawi, samples from 184 pregnant women enrolled early and 148 women enrolled late were assayed for antibody responses against P. falciparum antigens (Table 1) . At recruitment, women enrolled later were significantly heavier than the women enrolled earlier. The percentage of secundigravid women varied between 31.5% (early) and 46.6% (late; P = .02), ITN use increased from 19.0% (early) to 54.7% (late; P < .0001), and a higher percentage of women who enrolled later were taking more doses of SP (P = .005).
In the PNG cohort, samples from 131 pregnant women who were recruited early and 281 women recruited late were used (Table 2) . At the first ANC visit, women enrolled later were significantly older and had a greater mid-upper-arm circumference. Use of ITNs and malaria preventive drugs were significantly higher in women enrolled late (Table 2) .
Antibody Responses Against Schizont Extract, Merozoite
Antigens, and VAR2CSA-DBL5 ɛ
To determine malaria exposure, we assayed the antibody response to schizont extract. In both cohorts, women enrolled later exhibited significantly lower levels of antibody to schizont extract, indicative of reduced exposure. Prior studies have identified the merozoite antigens MSP2, MSP3, and PfRh2 [21, 23, 24] as targets of antibodies associated with immunity in nonpregnant individuals and VAR2CSA-DBL5 ɛ [29] as a highly immunogenic target associated with protection from low birth weight. Antibody responses to merozoite antigens and VAR2-CSA-DBL5 ɛ were significantly lower in later-enrolled women in both study population ( Figures 1A and 2A) . A similar significant decrease over time was observed in plasma samples collected at the first ANC visit in the PNG cohort (data not shown).
Opsonic Antibody Responses Against Whole Merozoites
The difference in antibody responses to each merozoite antigen observed in the PNG cohort led to the evaluation of the opsonic IgG response to whole merozoites. We restricted this analysis to delivery plasma from women in second and third pregnancies because the assays are resource intensive. Although women recruited later had lower IgG antibody responses to merozoite antigens, levels of opsonic IgG to whole merozoites did not vary over time (Z = 0.6; P = .5; Figure 2B ).
Total Antibodies Levels Against Infected Erythrocytes
In Malawian women, median levels of anti-VSA IgG antibody to E8B-ICAM declined over time (P < .01), but responses against CS2 did not vary ( Figure 1B) . In PNG, analysis of the same subset of women for opsonic IgG responses against whole merozoites revealed that median levels of anti-VSA IgG antibodies to both E8B-ICAM and CS2 declined over time (P < .01; Figure 2C ).
Opsonic Antibodies Against Infected Erythrocytes
Levels of opsonic IgG responses against E8B-ICAM and CS2 did not vary significantly over time in either study population ( Figures 1C and 2D ). In Malawi, the proportion of women with opsonic IgG antibodies to CS2 (early group, 85.2%; late group, 88.7%, P = .3) or E8B-ICAM (early group, 96.7%; late group, 96.0%; P = .7) did not differ between the 2 enrollment periods. In PNG, similar results were observed for CS2 (early group, 72.4%; late group, 63.0%; P = .08) and E8B-ICAM (early group, 90.8%; late group, 94.1%; P = .2). To determine whether differences in antibody titers were obscured by performing assays at concentrations above the saturation level, pooled plasma samples from each cohort and enrollment period were titrated. No significant differences in the dilution curves generated were observed (data not shown).
Analysis of Antibodies Against P. falciparum Antigens, Adjusted for Confounders
The changes in antibody responses over time, adjusted for confounding and interaction variables, are presented in Tables 3  and 4 . In the Malawian cohort, ITN use was associated with lower levels of IgG to schizont extract. The levels of IgG antibodies to MSP2, MSP3, VAR2CSA-DBL5ε, and VSA-CS2 were significantly lower as maternal weight increased. Additionally, levels of opsonic IgG against CS2 increased with gravidity, and women enrolled later who received a single dose of SP had significantly lower levels of IgG antibody to MSP2 (Table 3 ). In the PNG cohort, later enrollment was associated with significantly lower levels of IgG antibodies to schizont extract, MSP2, and MSP3 in the adjusted analyses. ITN use was associated with lower levels of IgG to schizont extract and MSP2. There was an important interaction between enrollment period and ITN use, such that women who enrolled later and who used an ITN had particularly low levels of IgG to MSP2 (Table 4) .
Changes in Antibody Responses Between the First ANC Visit and Delivery
We compared differences in antibody responses between the first ANC visit and delivery in the PNG cohort of women enrolled early or late. There was significantly more change between enrollment and delivery values in the early group, compared with the late group, for antibody responses to schizont extract, MSP2, MSP3, PfRh2, and VAR2CSA-DBL5 ɛ . Interestingly, women enrolled in the later period had an increased variability in levels of opsonizing antibody to CS2, which was largely confined to women in the SP and AZ treatment arm. In contrast, significantly more women who received SP and CQ had increases in their levels of opsonizing antibodies to E8B-ICAM, compared with women who received SP and AZ, Table 5 .
DISCUSSION
As malaria control intensifies, it is important to understand its impact on the development and maintenance of naturally acquired immunity to malaria during pregnancy. Examination of a range of antibody responses in 2 different settings revealed evidence of lower levels of humoral immunity in the more recent cohorts of pregnant women since intensification of malaria-control interventions, particularly in PNG. However, our results suggest that any decline in immunity with reduction in malaria transmission was modest and not evident across all measures of humoral immunity and that established immunity may be maintained for intervals at least as long as the time frame in our study. Although levels of some malaria antibodies measured by ELISA decreased, levels of opsonizing antibodies to intact parasites or IEs uniformly did not. Both settings experienced similar decreases in parasite prevalence, associated with increases in use of ITN and IPTp. Constant exposure may be more crucial in maintaining the levels of antibodies to specific antigenic determinants, such as the recombinant antigens used in our ELISAs, than to intact merozoites or IEs [17, 25] . In PNG women, a decline over time in total IgG levels to IEs may be due to reduced malaria exposure, suggesting that repeated exposure may be required to maintain antibodies against malaria [30, 31] . On the other hand, the development of opsonizing antibodies may be a better surrogate for protective immunity in areas with lower transmission.
Antibody responses to merozoite antigens are short-lived in young children [32, 33] but were better sustained in pregnant Data were calculated using multiple linear regression models. A positive coefficient implies an increase of antibody levels. A negative coefficient implies a decrease of antibody levels. P values of <.05 were considered statistically significant.
Abbreviations: CI, confidence interval; Coeff, coefficient; IgG, immunoglobulin G; SP, sulfadoxine-pyrimethamine. women [25] , and their prevalence is influenced by transmission intensity [34] [35] [36] . In the PNG cohort, a decrease in merozoite antibodies, as detected by ELISA, contrasted with no change in the levels of opsonic IgG against whole merozoites. This is the first assessment of changes in these functional opsonizing antibodies over time, and it suggests that opsonic IgG to merozoites may be more stable than antibodies to individual merozoite antigens. Given that opsonic IgG to merozoites was recently correlated with protection from clinical malaria in children [37] , persistence of these responses may be critical for maintenance of functional protective immunity in the face of declining transmission.
Of clinical importance for the development of a vaccine targeting pregnancy-specific VSAs [38] , levels of IgG against placental-binding IEs declined in the PNG cohort only, while levels of opsonic IgG to placental-binding IEs did not change in either cohort. The stability of the latter may be important given that opsonic IgG has been associated with protection against maternal anemia [39] and low birth weight [40] .
Adhesion-inhibiting antibodies are also associated with protection from complications of MiP [41] . We did not measure the ability of plasma to inhibit adhesion of IEs, but antibodies to VAR2CSA-DBL5 ɛ may inhibit adhesion of IEs to placental cells (although results are conflicting [26, 42] ). Pregnant women have a wide repertoire of antibodies against the VAR2-CSA-DBL5 ɛ domain, and these appear to be cross-reactive against placental isolates [16, 43] . Given that levels of IgG against VAR2CSA-DBL5 ɛ were lower in the later time points in both cohorts, this may indicate reduced ability to block placental sequestration of IEs at the population level. IgG against VAR2-CSA-DBL5 ɛ has been suggested to have a long half-life [25] , and consistent with this, individuals' responses to this antigen rarely decreased between enrollment and delivery. The lower levels seen in the late populations, compared with those in the early populations, may instead reflect reduced malaria exposure resulting in slower acquisition of anti-VAR2CSA-DBL5 ɛ . Prospective studies, performed over the course of a women's reproductive life, of the development of antibodies that opsonize IEs or merozoites or that block IEs adhesion, as well as their relationship to protection from infection, would be of great value [1] . In the Malawi cohort, enrollment period was not significantly associated with antibody levels after adjustment for confounders. Instead, ITN and maternal weight were independently associated with decline in levels of IgG against 1 or more antigens. Decreased exposure from increased ITN coverage may be driving the decline in antibody responses. The direct relationship between maternal weight and antibody was surprising. Women enrolled later were on average heavier, perhaps reflecting robust economic growth [44] and the declining prevalence of HIV infection [45] in Malawi. Maternal weight may be a proxy for other indicators of decreased parasite exposure and improved maternal health, including access to healthcare services. A declining prevalence of HIV infection could mitigate the drop in levels of IgG to placental-binding IEs, which are decreased by HIV infection [14] . As expected, levels of opsonic IgG to CS2 were gravidity dependent [1, 28] . Despite the lower force of infection, the gravidity-dependent acquisition of opsonic IgG to CS2 suggests that opsonic antibody to placentalbinding IEs may be carried forward to subsequent pregnancies.
In the PNG cohort, a significant association between antibody levels to some antigens and enrollment period remained after adjustment for confounders. Similarly, ITN use was associated with lower levels of antibodies, and for MSP2 antibodies there was evidence of an important interaction between enrollment period and ITN use. Both IPTp and ITNs have previously been shown to decrease development of pregnancy-specific immunity (but not of other measures of malaria immunity) [11] [12] [13] . Women who begin using ITNs early during pregnancy may be protected against malaria during early fetal development, but increased ITN use by women in the later group may have reduced malaria exposure and led to a decline in antibody responses.
Antibody levels vary over a malaria season [34] or a single pregnancy [25, 28] . In PNG, among women who were negative for parasitemia at antenatal booking and at delivery, a high proportion of in the early group experienced changes in levels of antibody to merozoite antigens and VAR2CSA-DBL5 ɛ , whereas more responses were unchanged among women in the later group, consistent with a lower force of infection. By contrast, levels of opsonic IgG to CS2 became more variable with time. When we compared changes in antibody responses by treatment arm, responses measured by ELISA rarely changed, and this did not differ by intervention arm, but levels of opsonic IgG to E8B-ICAM increased more frequently among women receiving a single course of SP with CQ. By contrast, women receiving more-intensive IPTp with SP and AZ more often had declining levels of opsonic IgG against placental-binding IEs [11] , probably reflecting decreased exposure to malaria.
Pregnant women infected with HIV have reduced levels of antibodies to P. falciparum antigens [14, 44] . HIV infection is uncommon in pregnant women in PNG, and we lacked information regarding HIV status in Malawian women, so we could not address this factor. Evidence of past malaria detected by placental histologic analysis is associated with higher levels of antibodies [46] . We did not examine this, but in the PNG cohort, in which samples were obtained at ANC booking and delivery, the decline in antibody responses between periods was similar, making it unlikely that past infection confounded our findings. Future studies should address these questions.
In conclusion, the impact of falling parasite prevalence on anti-P. falciparum serological indicators in pregnant women differed between settings. There were limited changes over time in Malawian women after adjustment for other important cofactors, but in PNG, decreases in several antibody responses remained significant after adjustment. For antibodies to IEs, findings varied depending on the assay used. The parasite prevalences in PNG and Malawi were quite similar in both the early and late groups. ITN use was associated with lower levels of antimalarial antibodies and might increase women's susceptibility to malaria in subsequent pregnancies. Whether malaria transmission has declined overall in these 2 populations is currently unknown, but differences in local transmission might explain differences between the sites. Continued monitoring of the immunity of susceptible populations, including assays that measure level of antibodies to intact cells, will be important as malaria control intensifies.
Notes
